GS-4321 Placebo

DRUG2 trials

Sponsors

Gilead Sciences Inc., Gilead Sciences

Conditions

Chronic Hepatitis DeltaChronic Hepatitis Delta.

Phase 1

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

RecruitingNCT07096193

Gilead SciencesChronic Hepatitis Delta

Start: 2025-07-31End: 2030-01-01Target: 200Updated: 2026-08-27

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.

Not yet recruitingCTIS2025-522729-36-00

Gilead Sciences Inc.Chronic Hepatitis Delta.

Target: 3Updated: 2026-02-09